to the have areas, morning Thank it with our we In thank and and you built you, for the innovation that delivering will today. is an started to And transformation I great Today, with Buell. us. speed. us update In XXXX, our immuno-oncology Agenus, and we engine. four of interest intent Dr. are quarterly good achievements for to joining an in progress years, of which a three company past you describe make
prior pass We of our months the a have easy to we on is CTLA-X and PD-X INDs programs, evidence filed to advancing a into XXXX. made the clinic for five in which filing. and and The First, substantial in progress clinic progress discoveries in potential our track. start XX the our are the BLA delivering for
filed. of already first half additional working on filing sixth are two this of more been year, track the which three we IND XXXX. in file to Our are INDs for have Furthermore, programs
to or tumor represents be from They pathways with research products best-in-class first-in-class address potential to All the pipeline resistant major immuno-oncology. breakthroughs and either in of these designed our compounds. the represent next our discoveries also
progressing In planned proprietary filing I XXXX. our in are a towards alluded antibodies PD-X addition, BLA as to, CTLA-X and
Second, sheet. concerns issues related and balance I address know are will these discuss our and that cash I aware them. we position will of to Please
we pace. INDs the our and same filing I time, At cash programs mentioned, satisfying will term record we hear are a as at progressing are you needs. As our near prudently shortly,
our Third, on recent new progress establishing partnerships. I strategic will an provide in update
I very our We what these year. your in potentially cash balance Agenus us, expect I is significant mind result important will to infusions sheet. with is which to something into believe in start this and
our balance the was it the Our dilution quarter same shareholders. end positions we the our been been cash XXXX and the said and cash at of advancing compelling prudently $XX second before, we have million, minimize At to managing to intent QX with $XX as in million pipeline closed cash. an I We've $XX exciting At end time, with million. of programs. was of
expected will prudently to the this our What Hence levels. end above speak current is prospects, innovative quarter, We our the immuno-oncology Until we I I critically partnership current we will manage continue quarter, position that cash our means at is third that of is or be finances. is near to cash, additional them our to XX secure major important. advancing about drivers. plus near-term value expect these rapidly which be when discuss candidates
discussions. outline I partnering status mind, our provide of will Next will activities. which of transparency first prior and these the while is I this update on pressing is our in our respecting sensitivity the partnering item, calls. strategy everybody's plans an with in
a to with to time and maximize that to inspite we announcement fit. has it our have not on shareholders close Agenus, value to we of working However, an transaction, additional taken yet are made the the right
has to-date. IO what prospective types is to landscape, we're partner speak and and IO pursuing the this the transaction in immuno-oncology; that has profiles Let obviously me influenced how changed first
first in-license to efficacy the safety The ago. intent it of assets even first-in-class is are appreciated successes Either failures is compounds of belong to assets first the following Most the today past major alone. immuno-oncology months to that with categories. stage year pathways was risks. change with and explore or an better biopharma development six clinical and complimentary biologic for, mitigate in unanticipated one than and in companies looking The multifunctional complexity later clinic data
year, Over have we our substantial bispecific be we timeline decision late strengthened then year the stage immuno-oncology resulted Because agents To of made new accelerate in attracted our is of as immunosuppressive from these interest pathways advancing this? approved, address categories. in Since last the clinical a months. why advancement well deliberate And by today. first-in-class pipeline, with modulate limitations have This they that programs as our currently multiple partners. past specific, to these programs. of position the both two six of
advanced also and our PD-X programs. We CTLA-X
partners, the our and continued that explore of their combinations agents from competitor therapies superior and generated with immuno-oncology We agents. antibodies. antibodies space, new equivalent if foundational interest foundational to are seeking immuno-oncology perspective has a establish not This to confirmed own, these footprint novel in
and and have the new The resources that in Agenus companies broad portfolio second has immuno-oncology has field. significant deep major players change and immuno-oncology pipeline also partnership advance therapies invested been built. are antibodies sophisticated Agenus' financial part bispecific is to of These the time significant understanding the specifically of our resources vaccines commercial that can rights while ourselves. field. broad pipeline, offer unparalleled to cell portfolio our entering retaining A in and
So, broad announcement more the a Multiple working bring to over weeks. next and quarter, for XX/X strategic mean last what of discussions one early us? we're as eight matured of have closure to as or currently date, to with does possibly the transactions them this all target
our I partnerships partnerships. with in progress obligations with made we've To-date, words and the we our all with a say few on delivered Merck, Incyte, will Next, our with have about GSK. existing
IND is expected exceeded to by filing, have expect the achieved current milestones We year-end. or milestones. third a that In been we quarter, already two commercialization or research, and around have and receive for payments additional met all
a Our QS-XX very vaccine. know as important add Shingrix component adjuvant component and a I you of might GSK's is
be coverage, from I ahead additional from sales This summary Shingrix recent earlier the These under call with agreement discoveries TIM-X quarter royalty in our of may IND transactions operational of of Dr. antibodies include turn our first LAG-X - our before first activities actually. Gupta, our resulted substantially and three forecast, media in you year making the partnership fillings. likely. three half for As lastly, aware of year fillings for Sunil Incyte. the provide milestones are more to I will And
We next-generation also AutoSynVax, we neoantigen IND, call which filed third a ASV. covers it our vaccine,
developing Tregs with T-cell in rather. next our our ASV CTLA-X while to IND antibody. will priming for be designed The expect to PD-X neoantigen and improving We CTLA-X be deplete our filing combination vaccine next-generation
and called this publication earlier Cancer Our this are Cell. a in discoveries covering antibodies T-reviewed high impact year other published journal in the
next-gen products. of Our safety to advantages molecules to clinical potential has our address immuno-oncology the and stage and relative approved limitations current and both efficacy CTLA-X is designed
of of to to better are care CTLA-X antitumor IND bispecific to standard of The mechanisms file multiple and these a immune our thirst improves first-in-class for on track when and also our other microenvironment we tumor combined next-gen enable immunotherapies. addition response INDs two antibodies. to filing, with In
tumor but Tregs microenvironment, specifically in not periphery. in deplete the the second The
the critical agent current of is These that We microenvironment this. offer treatments. the conditioning any are of other two of not space to also doing aware in immuno-oncology overcoming immuno-oncology tumor capable agents solutions limitations
are as as compounds, hear more specifically. year we as on well course clinics about specifics will enter the talk these You they their likely more to enter - early next identities of
I speed are our advances and As clinical said meaningful innovations before, dogma. for
mono multi-specific and classes, four adjuvants. antibodies, cellular our pipeline Our modulating have discovery and vaccines, therapies, checkpoint platforms enabled of therapeutic neoantigen
to an Our to which advancing enable development be line in and cell fast platforms manufacturing LA filings. us INDs advantage give products path
speed have first-in-man CTLA-X is and PDX our trial after filing as commence. monotherapy our in demonstrated combinations the potential BLA XXXX. This early towards four years We as just advancing
our records programs. earlier grade of year, set for this production Additionally, products bispecific we lead for GMP
ever any manufacturing be of scale in one. to bank they AGENXXXX because INDs conventional of us may antibody from two months our even fastest development though Our compound to a the four surpassing and is in without accomplishments completed years for would highlight the so in under timelines to development cell knowledge our at research to not impossible you them exciting it span. even sound these I to many want be industry filing
AACR approximately This PD-X of anticipate a year me benefit the turn and ASCO and that antibodies to our CTLA-X data at at We monotherapy benefited we our presenting progress pharmacodynamic treated a have of antibodies patients To-date the PD-X anti-CTLA-X molecule than on Let of clinical XXX presented total and forward durable. our with and AGENXXXX clinical we be is both ASCO. compelling XX% separately more robust reported patients. combinations. this later our generated to at more data activity importantly anti-PD-X year. more in We even look in PD-X treated and clinic. updated that to We now
CTLA-X patient over sarcoma exciting complete ASCO showing to and at had the patients AGENXXXX free of durable trial year was prior This in have patient And clinical one multiple reported CTLA-X refractory source to is lower We our disease today that who results later. monotherapy our treated XX% molecule. with a our from a cancers with benefit. refractory response treatments remains
Sunil are advancing anticipate cervical in three an a that refractory with PD-X our XXXX. and trials a durability in this indication, the detail significant take clinical alone. regulatory designed response monotherapy setting as PD-X plans advantage clinical of is PD-X be filings plus unmet pathways patients as patients cervical and in expand head And refractory cancer trials active early will need Two, programs Our to pharmacovigilance of - more Dr. in responses three, cancer. because for is active CTLA-X describe include further in same are CTLA-X monotherapy PD-X In of colleague we to and to BLA today. clinical approval, this rate and combinations CTLA-X monotherapies important our in to-date accelerated day. just and summary, will Gupta My in
in that patients All patient oncology experts impressed so had of catalyzed record small terrific with including Avastin our numbers of key is short-term our clinical patients opinion findings trial group a relatively These cancer. and far track a This leader benefit approval endpoints have for and for called same. for cancers. topotecan gynecological the these enrollment the In trial require particularly and and with observed for of the exciting gynecologic approval we recent cervical successes later engagement GOG. group trials
CTLA-X advance our same and the in PD-X us. year At $XX commitment line time, to these second expected with This are are commercial cervical provide revenues $XX to - for for important target Our to numbers specifically forecast have efforts opportunities access programs these much aggregate as several there in exemplifies as be agent that commercial limitations. effective And options current initiatives cancer to alone agents our treatment years reach anybody billion. billion. will represent
have large portion of unfortunately in expect meaningful paths us the XX,XXX cervical We line cancer U.S. cases deaths and development defined the including second There cervical to will cancer which enable of X,XXX are a we capture new several this market. are annually alone.
nearly had our and as distinguished Dr. it's regulatory most inhibition who I trained where regulators And guidance a Dr. individuals which pleasure of Dr. medical leadership Gupta cabazitaxel. Dr. trained is filings As secure a inhibitor background under Gupta. in XX Sunil? approval filings leading veteran is team Sunil I several oncologist is to I and included oxaliplatin the understated He my with with is positions. the have one call Gupta career superb we a PARP or from years an and anti-PD-X, met. said, to the engage regulatory XX-year he of strategist Sanofi the of say our aggressively us turn Gupta. a industry joins plans, might BLA of senior
